04891nam a2200421za 45000010014000000030008000140050017000220070015000390080041000540200028000950200025001230220014001480400026001620720016001880720 01500204072001500219082001500234245010600249260005400355365011000409365007300519366003500592366004400627490003600671500004700707 50511860075451600130194052014230195354507890337665000340416565000330419965000330423270000230426570000200428870000230430885600660 43318560072043979781849840989UK-WkNB20180814000000.0cu||||||||||||180814e201809uuxxk |s|||||||0|0 eng|d a9781849840989 :c$85.00 a1849840989 :c$85.00 a2312-5098 aUK-WkNBbengcUK-WkNB 7aMJL2bicssc 7aHEA2ukslc 7aMJL2thema04a616.2322310aBronchietasish[electronic resource] /cEdited by James D. Chalmers, Eva Polverino, Stefano Aliberti. aSheffield :bEuropean Respiratory Society,c2018. a02b85.00cUSDd00eThis price includes a tax elementhZ 85.00 0.00 85.00 0.00jGBkxxkmTEDITOR2onix-pt a02b85.00cUSDd00eLocal taxes may applyjUSkxxumTEDITOR2onix-pt b20180901cIPjGBkxxk2UK-WkNB b20180901cIP 20180907jUSkxxu2UK-WkNB0 aERS Monograph,x2312-5098 ;v81 aElectronic book text. Text (eye-readable).0 aA patient's perspective-- Pathophysiology-- Identifying undiagnosed cystic fibrosis in adults with bronchiectasis-- Comorbidities and their impact-- Defining severe bronchiectasis-- the bronchiectasis microbiome-- How do we know what works? Clinical trial end-points and quality of life assessment-- Phenotypes and endotypes-- Primary immunodeficiency-- COPD and asthma overlap with bronchiectasis-- Fungal lung disease-- Diagnosis, classification and epidemiology of pulmonary nontuberculous mycobacterial disease-- Management of pulmonary nontuberculous mycobacteria disease-- Nontuberculous mycobacteria infections in patients receiving immunosuppressive agents-- Systemic and connective tissue diseases-- Diagnosis of primary ciliary dyskinesia: current practice and future perspectives-- Management of primary ciliary dyskinesia: current practice and future perspectives-- Management of frequently exacerbating patients-- Antibiotic management and resistance-- Airway clearance techniques, pulmonary rehabilitation and physical activity-- Site of care and multidisciplinary approach-- Future directions: the next 10 years-- Case 1-- Case 2-- Case 3-- Case 4-- Case 5-- Case 6. aDocument aThis Monograph provides a series of chapters from recognised world experts covering: clinical management, service delivery, pathophysiology, microbiology and underlying disorders. The book also addresses the challenges faced in clinical trials and the need for drug development, and presents a number of clinical cases designed to aid learning.bBronchiectasis is a hot topic in respiratory medicine, attracting an increasing amount of interest from clinicians, scientists, physiotherapists and the pharmaceutical industry. However, there is a lack of knowledge about the disease in terms of the research performed, clinical management, classification and patient treatment. The disease is also very complex because it can be caused by multiple underlying disorders, meaning its clinical presentation is highly diverse. This Monograph will tackle these issues by providing a series of chapters from recognised world experts covering: clinical management, service delivery, pathophysiology, microbiology and underlying disorders. The book also addresses the challenges faced in clinical trials and the need for drug development, and presents a number of clinical cases designed to aid learning. The Bronchiectasis Monograph substantially integrates the 2017 ERS guidelines on management of these patients. It is an essential reference for anyone caring for bronchiectasis patients or engaged in bronchiectasis research.0 aJames D. Chalmers is GSK/British Lung Foundation Professor of Respiratory Research and Honorary Consultant Respiratory Physician at the University of Dundee/Ninewells Hospital (Dundee, UK). He runs a regional specialist clinic for over 600 patients with bronchiectasis and is coordinator of the ERN Lung core network for bronchiectasis. Eva Polverino is an expert in respiratory infections and leads research into bronchiectasis and cystic fibrosis at Vall d'Hebron University Hospital in Barcelona (Spain). Stefano Aliberti is Professor of Respiratory Medicine at the University of Milan (Milan, Italy), and consultant at the Policlinico Hospital in Milan (Milan, Italy). He is the director of the bronchiectasis and primary ciliary dyskinesia programmes at the Policlinico Hospital. 7aRespiratory medicine.2bicssc 7aHealth and Wellbeing.2ukslc 7aRespiratory medicine.2thema1 aChalmers, James D.1 aPolverino, Eva.1 aAliberti, Stefano.4 uhttp://www.ersbookshop.comx01zPublisher's corporate website4 uhttp://www.books.ersjournals.comx01zPublisher's corporate website